Navigation Links
Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
Date:4/10/2008

Data Presented at the 10th Annual Superbugs and Superdrugs Conference on

Antibacterials

WATERTOWN, Mass., April 10 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, today announced the presentation of their breakthrough research program to evaluate a new macrolide-related drug class, Bicyclolides, in the treatment of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and other gram-positive infection pathogens. Enanta's Bicyclolides have also demonstrated strong activity against MRSA strains resistant to vancomycin, Zyvox(R) (linezolid), and CUBICIN(R) (daptomycin).

The oral presentation, "New Bicyclolides Active Against MRSA and VRE," was presented today during the 10th Annual Superbugs and Superdrugs Conference in London, England.

"Previously, MRSA infection was a problem mainly for patients treated in hospitals," said Robert Moellering, M.D., a professor of medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. "Now we're seeing MRSA in the general community, creating a tremendous need for a new class of antibiotics with improved safety profile and more convenient administration for use within both hospital as well as community settings. The growing problem of bacterial resistance to many existing drugs also necessitates the development of new classes of compounds to fight the battle."

"Pre-clinical research on these new Bicyclolide compounds revealed activity against MRSA and VRE, even against highly drug-resistant MRSA strains. This was an unexpected finding, because traditional macrolides do not work against these bacteria," explained Yat Sun Or, Ph.D., Senior Vice President of Research and Development at Enanta. "These results are also very exciting, because we have observed activity as good as intravenously-administered vancomycin or Zyvox(R) with oral once-a-day dosing lev
'/>"/>

SOURCE Enanta Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. NPS Reports Successful GATTEX(TM) Extension Study
9. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
10. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
11. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... UBM Medica US announces that Neurology Times ... for neurologists and other healthcare providers, features special coverage on ... discussions of the latest developments in approaches to diagnosis. ... , more than the total of those who have multiple ... can be difficult because there are no confirmatory medical tests. ...
(Date:10/17/2014)... Oct. 17, 2014 A victim of medical negligence ... doctor with a history of alcohol abuse, a physician ... on Prop 46 today, highlighting how Prop 46 will identify ... testing. The ad pictures a doctor drinking ... To ER."  Proposition 46 will enact the first law in ...
(Date:10/17/2014)... 2014   InnFocus, Inc ., reported on results of ... for up to 3 years with the InnFocus ... Chicago . The Summit ... meeting of the American Academy of Ophthalmology . The ... glaucoma patients in 6 countries by early 2015. ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
... LITTLE FALLS, N.J. , May 26 CANTEL ... Andrew A. Krakauer , President & CEO, will be presenting at the ... 9:00 AM ET on Wednesday, June 9, 2010 ... a Q & A session immediately following the presentation. In addition, Mr. ...
... BOSTON , May 26 Solos Endoscopy, Inc. ... $104,774 in revenues for the first quarter ended ... the first quarter 2009, which represents a 10 percent increase. As ... in total assets. The Company has posted its financial results for ...
Cached Medicine Technology:Cantel Medical Corp. to Present at the Jefferies 2010 Global Life Sciences Conference 2Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009 2
(Date:10/20/2014)... San Diego, CA (PRWEB) October 20, 2014 ... regarding all the latest information from the FDA on ... consumers on October 10 not to purchase or use Sit ... Phenolphthalein. Sit and Slim II is promoted as weight loss ... , Sibutramine, removed from the market in 2010 for safety ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... Aliso Viejo, California (PRWEB) October 20, 2014 ... have announced the release of the Citrus theme for ... words I would use to describe the Citrus theme” Says ... been so easy to look so professional.” , Citrus comes ... . Included with the template are: four transitions for added ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... learned that you were at high risk of cancer because ... your children? A recent study at Fox Chase Cancer Center ... the next level and studied the parent perceptions of the ... be presented at the 2009 Annual Meeting of the American ...
... Chase Cancer Center uncovered a genetic pattern that may ... to the targeted therapy imatinib mesylate (Gleevec). Moreover, ... in order to make these tumors respond more readily ... in the laboratory of Andrew K. Godwin, PhD, at ...
... new pharmaceutical products in the pipeline combined with new ... the rare disease community, a senior Food and Drug ... by the National Organization for Rare Disorders (NORD).The blockbuster ... director of the Center for Drug Evaluation and Research ...
... 14 Hanger Orthopedic Group Inc. (NYSE: ... in the S&P SmallCap 600 after the close of trading ... acquired by privately held TriNet Group, Inc. in a transaction ... and post any relevant updates on its website: ...
... MedServe, Inc., a private company, today announced that it ... Stericycle, Inc. (Nasdaq: SRCL ) for $185 ... Avista Capital Partners, Chrysalis Ventures and Murphree Venture Partners ... collection, transportation, treatment and disposal of medical waste, hazardous ...
... ImQuest Bio and Arisyn jointly presented important ... inhibitor of hepatitis C virus (HCV) replication, at the 13th ... presentation highlighted the ability of PG301029 to potently suppress the ... potential mechanism of antiviral action through the selection of a ...
Cached Medicine News:Health News:Should parents share the results of BRCA1/2 genetic testing with their children? 2Health News:Gene signature may predict patient response to therapy for gastrointestinal stromal tumors 2Health News:NORD Sponsors Rare Disease Summit 2Health News:Standard & Poor's Announces Changes to U.S. Index 2Health News:MedServe to be Acquired by Stericycle for $185 Million 2Health News:MedServe to be Acquired by Stericycle for $185 Million 3Health News:ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference 2
... of Surgical Microscope Accessories includes digital camera ... cables, and fiberoptic retrofits. TTI Medical's patented ... 5,264,928) is the only adaptor that will ... the same adaptor body. It is fully ...
... Electronic Medical Record system. It stores patient chart ... and everything you would normally put in a ... Someone has to write them, file them, find ... Paper Charts get lost. They find their way ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
... WAVEFRONT ANALYZER provides a complete ... the entire eye. Real-time measurements ... aberrations in many different forms ... higher order aberrations, Zernike polynomials, ...
Medicine Products: